IFF outlines a Scent recovery driven by a strengthened R&D pipeline, improved go-to-market execution, and a strategy to lift market share across Fine and Consumer Fragrance. The company anticipates a softer Q3 but a stronger Q4 for Fine Fragrance and a normalization to low single-digit growth for Consumer Fragrance in H2, supported by an 8-9% of sales R&D investment through 2027.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
What are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Management describes the prior R&D pipeline as “not what it should have been” about 2.5 years ago, and states that today IFF has a “very strong R&D capability,” a “great R&D team,” “great perfumers,” and a “great pipeline of molecules as well as delivery systems.” 1 This matters because it supports the company’s stated objective to restore balance between investing in R&D, rebuilding go-to-market execution, and regaining market share. 2
For Fine Fragrance, management attributes the near-term recovery to (1) successfully managing uncertainty/volatility related to the Middle East and (2) navigating against very difficult year-ago growth comparisons—specifically noting that Q3 2025 Fine Fragrance grew about 20%. 3 They also reported that while they expected mid-single-digit growth decline entering Q2 due to the Middle East, Fine Fragrance “finished up slightly positive.” 3
Management says Scent’s Q2 performance was driven by Fragrance Ingredients growing “north of 20%,” and they explicitly separate two components: (a) favorable year-over-year comparison (comparing to a year-ago period that was down “10% or more”) and (b) underlying demand capturing macro/supply-chain/sustainability effects via strategic leverage of the synthetics portfolio “including… higher Brent crude prices.” 3 They then expect normalization in the second half, with growth shifting “back towards the higher value-added ingredients versus the traditional synthetics.” 3
Management links the Consumer Fragrance recovery to rebuilding R&D capability and a “go-to-market approach with customers,” explicitly aiming to drive “market share gains.” 4
Scent delivered sales growth of “8%” (to $665 million) and profitability improvement, with Scent EBITDA growing “5% to $134 million.” 5 Management attributes profitability gains to “volume growth and productivity gains.” 5
Management frames Fine Fragrance as “a little bit softer in Q3, but a stronger Q4,” resulting in a “second half basis in the mid-single-digit range.” 4 The underlying rationale includes continued Middle East-related effects and large comps (e.g., Q3 last year up ~20%), but with recovery visibility improving into Q4. 3
Bottom line for Fine Fragrance in H2: weaker sequential pattern early (Q3) with recovery accelerating by Q4, targeting mid-single-digit growth across the half. 43
For Consumer Fragrance, management says the business is “in that low single-digit range,” noting Q2 was high single-digit but is expected to normalize “on a go-forward basis” to low single digits. 4
Bottom line for Consumer Fragrance in H2: roughly low single-digit growth overall, with normalization from the strong Q2 print. 4
Management emphasizes that the company has strengthened R&D capability over the last ~2.5 years—moving from a weak pipeline to “leading-edge new Fine Fragrances and Consumer Fragrances,” supported by “molecules” and “delivery systems.” 1 This is presented as part of a broader initiative to restore the right balance: investing in R&D, regaining market share, and strengthening go-to-market with customers. 24
They explicitly credit the team with doing a “good job on the compounds” and rebuilding the “R&D capability [and] go-to-market approach with customers,” aiming to drive market share gains in Consumer Fragrance. 4 That is the mechanism described for turning R&D output into commercial traction.
While the question asks specifically about 2027 R&D support, the excerpts provide a relevant timing signal: for Fragrance Ingredients, management says the shift to “higher-value natural products” is underway and “will take a little bit more time, not in the second half of this year. But as we go into next year and the year after, we believe we’ll have a really strong competitive position.” 4 This implies the R&D/technology/product mix transition is intended to strengthen competitive position beyond 2026 and into the 2027 timeframe. 4
Management states it is “very optimistic about the future of Scent” given progress in strengthening the R&D pipeline and addressing gaps, while also saying “we’re not satisfied” and “a lot more to do.” 1 In addition, they highlight the importance of continued reinvestment in innovation/innovation-led growth as part of the broader transformation framework (including a focus on maintaining R&D investment levels around 8%–9% of sales for the transformed business). 6
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
IFF's Scent segment posted an 8% Q2 sales rise led by double-digit growth in Fragrance Ingredients and a resilient Consumer Fragrance line, even as Fine Fragrance faced Middle East volatility. The firm outlines a two-track H2: mid-single-digit growth for Fine Fragrance with a Q3 soft patch and a rebound in Q4, while Consumer Fragrance normalizes after a standout Q2, underpinned by an R&D-driven push into 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery is advancing on multiple fronts, led by volume-driven growth, a re-energized R&D pipeline, and stable management of regional volatility. In 2H, Fine Fragrance should soften in Q3 and rebound in Q4, while Consumer Fragrance normalizes to a low single-digit pace, with 2027 R&D investments positioned to bolster long-term competitive strength.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Management ties the Scent recovery to a significantly stronger R&D pipeline and execution, with Scent sales up 8% and EBITDA up 5% driven by volume gains and productivity. For 2H, Fine Fragrance is expected to be soft in Q3 but stronger in Q4, while Consumer Fragrance should normalize to low-single-digit growth; the 2027 plan emphasizes sustained R&D investment, perfumer-led innovation, and a shift toward higher-value natural ingredients.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery is led by Fragrance Ingredients and volume gains, with Fine Fragrance expected to be softer in Q3 and rebound in Q4. The company emphasizes a rebuilt R&D pipeline and higher-value product shifts to support competitive positioning into 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF Scent’s recovery hinges on a rebuilt R&D engine and market-share gains in Consumer Fragrance, with Fine Fragrance stabilizing amid Middle East volatility and Fragrance Ingredients normalization. In H2, Fine Fragrance is expected to soften in Q3 and strengthen in Q4, while Consumer Fragrance normalizes to low single-digit growth; management also emphasizes sustaining R&D investment around 8-9% of sales to support 2027 competitiveness.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery driven by Fragrance Ingredients momentum and a robust R&D build, with Fine Fragrance softening in Q3 and strengthening in Q4, while Consumer Fragrance stabilizes through renewed R&D and go-to-market execution ahead of 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery hinges on a rebuilt R&D engine, better market execution for Consumer Fragrance, and disciplined volatility management in Fine Fragrance amid Middle East challenges. Q3 is expected to soften, while Q4 aims for a meaningful recovery; Fragrance Ingredients momentum should normalize toward higher-value inputs. The company frames a stronger R&D pipeline as the cornerstone of the 2027 growth trajectory.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent rebound hinges on stabilizing Fine Fragrance amid Middle East volatility, with Q3 softness and Q4 rebound, while Consumer Fragrance recovery relies on rebuilt R&D go-to-market capabilities and market-share gains. Fragrance Ingredients provide momentum that is expected to normalize in 2H, underpinning a stronger 2027 pipeline and competitive positioning.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery anchored in disciplined reinvestment in R&D, a strengthened pipeline, and careful navigation of Middle East volatility, with 2H 2026 expected growth in Fine Fragrance and a normalization to low single digits in Consumer Fragrance. The multi-year R&D plan targets 2027 by advancing molecules, delivery systems, and leading‑edge perfumers to sustain competitive advantage.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF frames Scent's recovery around a rebuilt, stronger R&D pipeline and innovative delivery systems, with Fragrance Ingredients accelerating on higher-value inputs. For H2, Fine Fragrance should see a softer Q3 followed by a stronger Q4, while Consumer Fragrance is expected to grow in the low single digits as R&D and go-to-market efforts support market-share gains—backed by an ongoing 8-9% R&D investment to fuel 2027 growth.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery hinges on a rebuilt R&D engine, stronger go-to-market execution, and resilient Fine Fragrance performance amid regional volatility. In H2, Fine Fragrance is expected to deliver mid-single-digit growth with a soft Q3 and stronger Q4, while Consumer Fragrance normalizes to low single-digit gains; the company reiterates a 2027-focused plan to sustain innovation through heightened R&D investment and a robust molecule and delivery-systems pipeline.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Management outlines a disciplined capex path for Remainco, signaling capex around 5–6% of sales and R&D around 8–9% as a post-divestiture growth engine. They stress reinvestment to fuel innovation, margin expansion, and ongoing value creation, while noting near-term headwinds from the stand-alone transition.
Sources used
Research questionWhat did management say about Capex and reinvestment post-divestiture?
Answer outline
Dafinchi